RT Journal Article
SR Electronic
T1 Stable IgG-antibody levels in patients with mild SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.16.21258960
DO 10.1101/2021.06.16.21258960
A1 Thomas Åkerlund
A1 Katherina Zakikhany
A1 Charlotta Löfström
A1 Evelina Lindmark
A1 Henrik Källberg
A1 Ulla Elofsson
A1 Karin Cederbrant
A1 Erik Nygren
A1 Anders Kallin
A1 Nina Lagerqvist
A1 Peter Nilsson
A1 Sophia Hober
A1 Anna Ridderstad Wollberg
A1 Åsa Szekely Björndal
YR 2021
UL http://medrxiv.org/content/early/2021/06/18/2021.06.16.21258960.abstract
AB More knowledge regarding persistence of antibody response to SARS-CoV-2 infections in the general population with mild symptoms is needed. We measured and compared levels of SARS-CoV-2 spike- and nucleocapsid-specific IgG-antibodies in serum samples from 145 laboratory-confirmed COVID-19 cases and 324 non-cases. The IgG-antibody levels against the spike protein in cases were stable over the time-period studied (14 to 256 days), while antibody levels against the nucleocapsid protein decreased over time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was exclusively funded by the Public Health Agency of Sweden via an assignment (S2020_05026) from the Ministry of Health and Social Affairs, Government of Sweden.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was obtained from the Swedish Ethical Review Board: Dnr 2020-03584.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in the manuscript and appendix. Data is not available at other URLs.